Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus chemotherapy as neoadjuvant and adjuvant treatment for stage IIIA non-small cell lung cancer
ChiCTR1900025813Phase 4Not yet recruiting
- Sponsor
- Nantong University
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Nantong University. Primary endpoints: PD-L1 and Ki-67. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900025813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025813.